Although several combination chemotherapy regimens can produce response rates of more than 20% in unresectable non small cell lung cancer (NSCLC), the impact on survival is debatable and at best -albeit statistically significantmarginal (Rapp et al., 1988; Williams et al., 1990) . One approach to improve these results is to explore the doseresponse relationship of cytotoxic drugs. For anthracyclines a number of cancer models (Frei et al., 1980; Razak et al., 1972) and phase I II studies (Cortes et al., 1978; Yates et al., 1982; Wheeler et al., 1982; Preisler et al., 1984; CarmoPereira et al., 1986; Jones et al., 1987) are indicative for such a relationship. The use of Doxorubicin (DOX) is limited by a number of side effects, in particular a dose-related cardiomyopathy. In order to overcome this problem, a series of DOX analogues have been synthesised. One of these is 4'-epidoxorubicin (Epirubicin (EPI)). Its spectrum of activity was found to be virtually identical to that of DOX. though the therapeutic index of EPI was more favourable, especially in regard to cardiac toxicity (Torti et al.. 1986; Nielsen et al.. 1990) .
In the majority of phase I-II studies published. the dose of EPI used was 75-90 mg m-2 on a 3 week schedule. However. the favourable therapeutic index of EPI, led to a second generation of phase I studies (Case et al., 1987; Case et al.. 1988; Feld et al., 1988; Karp et al., 1989; Hickish et al., 1989; Tjuljandin et al., 1990; Holdener et al., 1988; Walde et al.. 1988) , in order to define a range of higher doses of EPI that could be safely administered as to deliver a higher doseintensity to non-hospitalised patients. (Mountain, 1986) .
The characteristics of the 25 patients entered into this trial are summarised in Table I (Nielsen et al., 1990 , Rozencweig et al., 1984 Shepherd et al., 1989 (Feld et al.. 1988 , Martoni et al., 1990 , Wils et al., 1990 show that at increased dose levels EPI may have activity in this malignancy (Table IV) . In a phase I study of EPI 55 mg m2 daily x 3 every 3 weeks Feld et al. (Feld et al., 1988) observed a 21% response rate, all PR, in previously untreated NSCLC patients. In a subsequently performed phase II study by the same group (Feld et al., 1990) 
